{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:51:56Z","timestamp":1761843116522},"reference-count":32,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":4298,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2001,6]]},"abstract":"<jats:p>Thalidomide is approved in the United States for treating erythema nodosum leprosum, a complication of leprosy. The present study determined the single\u2010dose oral pharmacokinetics and dose proportionality from 50 to 400 mg of Celgene's commercial Thalomid\u00ae thalidomide formulation in an open\u2010label, single\u2010dose, three\u2010way crossover study. Fifteen healthy subjects were given 50,200, and 400 mg of thalidomide on three occasions, and blood samples were collected over 48 hours. Pharmacokinetic parameters were determined using noncompartmental methods, and dose proportionality was assessed by linear regression of dosenormalized C<jats:sub>max<\/jats:sub> and AUC<jats:sub>0\u2010\u221e<\/jats:sub>. No serious or unexpected adverse events occurred. The most common adverse events were dizziness, somnolence, headache, and nausea. One patient was discontinued because of pharyngitis. There was a significant deviation from proportionality for C<jats:sub>max<\/jats:sub> with increases being less than proportional than changes in dose. AUC<jats:sub>0\u2010\u221e<\/jats:sub> increased proportionally with dose, suggesting that the overall amount of thalidomide absorbed, as well as its clearance, is independent of dose over the range used. V\/F was found to increase with dose. This was most likely due to the terminal rate constant, which is used to calculate V\/F, actually representing the absorption process rather than elimination (i.e., flip\u2010flop phenomenon). The terminal rate constant (absorption rate constant) for the highest dose was 50% less than for the other two lower doses. The less than proportional increases in C<jats:sub>max<\/jats:sub> were most likely due to thalidomide's low aqueous solubility. Thalidomide shows reasonable dose proportionality with respect to AUC from 50 to 400 mg.<\/jats:p>","DOI":"10.1177\/00912700122010555","type":"journal-article","created":{"date-parts":[[2003,7,19]],"date-time":"2003-07-19T09:38:13Z","timestamp":1058607493000},"page":"662-667","source":"Crossref","is-referenced-by-count":26,"title":["Thalidomide Dose Proportionality Assessment following Single Doses to Healthy Subjects"],"prefix":"10.1002","volume":"41","author":[{"given":"Steve K.","family":"Teo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Scheffler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin A.","family":"Kook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Tracewell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne A.","family":"Colburn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David I.","family":"Stirling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve D.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt196563303"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9926(199612)54:6<273::AID-TERA1>3.0.CO;2-#"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.4082"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/8466"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"e_1_2_1_7_2","first-page":"144a","article-title":"Phase I\/II study of carboplatin and thalidomide in recurrent glioblastoma multiforme [abstract 551]","volume":"18","author":"Glass J","year":"1999","journal-title":"Program\/Proceedings ASCO"},{"key":"e_1_2_1_8_2","first-page":"48a","article-title":"Thalidomide in the symptomatic treatment of cachexia in patients [abstract 178]","volume":"18","author":"Watanabe S","year":"1999","journal-title":"Program\/Proceedings ASCO"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70277-5"},{"key":"e_1_2_1_10_2","first-page":"53","article-title":"Anticytokine approaches to the treatment of anorexia and cachexia","volume":"25","author":"Haslett PA","year":"1998","journal-title":"Semin Oncol"},{"key":"e_1_2_1_11_2","first-page":"158","article-title":"Treatment of refractory rheumatoid arthritis\u2014the thalidomide experience","volume":"16","author":"Gutierrez\u2010Rodriguez O","year":"1989","journal-title":"J Rheumatol"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199204163261604"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3579(05)80196-7"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/314834"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.135.9.1079"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198808183190703"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.167.3.1211"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.177.6.1675"},{"key":"e_1_2_1_19_2","first-page":"621","article-title":"Attempted suicide with thalidomide: a case report","author":"Bresnahan T","year":"1962","journal-title":"Appl Therap"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-0461(2000)14:3<140::AID-JBT3>3.0.CO;2-P"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1965.tb02053.x"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008X(86)90449-7"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/chir.530060402"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00402227"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.12.2797"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1021\/js980172i"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1089\/088922299310331"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127009903901108"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/1099-081X(200001)21:1<33::AID-BDD213>3.0.CO;2-R"},{"key":"e_1_2_1_30_2","first-page":"308b","article-title":"Low\u2010dose thalidomide in patients with advanced refractory multiple myeloma [abstract 4603]","volume":"18","author":"Chen CI","year":"1999","journal-title":"Program\/Proceedings ASCO"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1985.166"},{"key":"e_1_2_1_32_2","first-page":"501","article-title":"The bioavailability of ultramicronized griseofulvin (GRIS\u2010PEG\u00ae) tablets in man","volume":"18","author":"Barrett W","year":"1975","journal-title":"Curr Ther Res"},{"key":"e_1_2_1_33_2","first-page":"402","article-title":"Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers","volume":"17","author":"Chen T\u2010L","year":"1989","journal-title":"Drug Metab Dispos"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F00912700122010555","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/00912700122010555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T14:37:19Z","timestamp":1700404639000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/00912700122010555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["10.1177\/00912700122010555"],"URL":"https:\/\/doi.org\/10.1177\/00912700122010555","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]}}}